The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies. Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies. New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Extracorporeal life support system with pulmonary and / or heart failure: Cytokine response
Timeframe: 24-48 hours
Extracorporeal life support system with pulmonary and / or heart failure: SOFA-Score
Timeframe: 24, 48, 72 hours
Extracorporeal life support system with pulmonary and / or heart failure
Timeframe: Time: first 72 hours
Patients with left ventricular assist device implantation: Difference of Cytokine response
Timeframe: 24-48 hours
Patients with left ventricular assist device implantation:vasopressors and / or inotropes
Timeframe: first 72 hours
Patients with left ventricular assist device implantation:Renal function
Timeframe: first 72 hours
Patients with left ventricular assist device implantation:Lactate level
Timeframe: first 72 hours
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of Cytokine response
Timeframe: 24-48 hours
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: SOFA-Score
Timeframe: 24, 48, 72 hours
Extracorporeal life support system with pulmonary and / or heart failure:Difference of mean arterial pressure
Timeframe: 24, 48, 72 hours
Extracorporeal life support system with pulmonary and / or heart failure: Difference of CVP
Timeframe: 24, 48, 72 hours
Extracorporeal life support system with pulmonary and / or heart failure: Serum lactate
Timeframe: 24, 48, 72 hours
Extracorporeal life support system with pulmonary and / or heart failure:Days on ventilator, vasopressor and renal replacement therapy
Timeframe: until day 30 post-surgery
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of mean arterial pressure
Timeframe: 24, 48, 72 hours
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of CVP
Timeframe: 24, 48, 72 hours
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Level of Serum lactate
Timeframe: 24, 48, 72 hours